BRAF and non-small cell lung carcinoma: reported an interesting case of synchronous G469V‐mutant NSCLC and BRAF WT hepatocellular carcinoma, in which sorafenib elicited partial response of the primary lung lesion, complete response of the he contralateral lung metastasis, and stable disease of the liver lesion.17